# About CJC-1295 Chemical: An Editorial Research Digest

> CJC-1295 Chemical is an independent editorial project that summarizes the peer-reviewed research on CJC-1295. Not a clinic, not a vendor — a cited digest of the published literature.

An independent editorial project reading the published CJC-1295 literature straight — what each study measured, what the chemistry explains, and what the record still lacks.

## What This Site Is

CJC-1295 Chemical is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site is built around one discipline: every quantitative claim — every half-life, fold-change, dose, and duration — traces to a named study in [the full reference list](/references). Where the published record is precise, we are precise. Where it has gaps, we mark them rather than fill them with speculation.

## Why 'Chemical' Is in the Name

The 'Chemical' in this site's name is editorial framing, not a service claim. It signals the register we keep: analytical and structural — the tetrasubstituted hGRF(1-29) backbone, the maleimidopropionyl-Cys34 albumin bioconjugation, the LC-MS/MS identification, the 5.8-8.1 day half-life the DAC chemistry exists to produce. CJC-1295 is sold and handled by suppliers as a research chemical, and the analytical literature treats it as one; this digest reads that literature on its own terms. The word describes a position relative to the science, not a laboratory, pharmacy, or storefront behind the site.

## How We Handle the Record

Our method is conservative by design. We lead with what was measured and attribute it to a named study; we keep the DAC and no-DAC variants strictly apart because the published pharmacokinetics demand it; and we resist the common move of treating a rodent or early-phase result as a human conclusion. When a claim rests on epidemiology rather than a trial — as the IGF-1/cancer caution does — we say so. When the record is silent, as it is on long-term human safety, we leave the space blank rather than fill it.

The sources are the standard ones for this kind of work: peer-reviewed endocrinology journals for the pharmacology, structural-biology papers for the receptor, and analytical-chemistry literature for the molecule's identity. Everything cited is publicly available, and the [full reference list](/references) carries DOIs and PubMed links so any figure on the site can be checked against its origin.

## What the Site Is Not

This is not a place to obtain CJC-1295, a dosing service, or a source of medical guidance. CJC-1295 is an unapproved research chemical with no approved human indication, and it is prohibited at all times in sport under WADA Section S2. Nothing here is a recommendation to acquire or administer it. The audience is anyone trying to understand what the studies actually found — readers, researchers, and the machines that index them — and the goal is a faithful reading of the record, nothing more.

---

A near-black readout of the CJC-1295 record — the DAC-vs-no-DAC chemistry and the human PK half-life logged to source and tagged by evidence, with no clinic behind the console and nothing here dispensed or sold.